BSD Medical Announces Sale of the MicroThermX® Microwave Ablation Systems in Turkey

  BSD Medical Announces Sale of the MicroThermX® Microwave Ablation Systems in
  Turkey

Business Wire

SALT LAKE CITY -- December 5, 2013

BSD Medical Corporation (NASDAQ: BSDM) (Company or BSD) (www.BSDMedical.com),
a leading provider of medical systems that utilize heat therapy to treat
cancer, today announced that the Company has received a purchase order for
multiple MicroThermX Microwave Ablation (MicroThermX) systems and antennas
from its exclusive distributor in Turkey, ADA Medikal (ADA). This is the
second order for multiple MicroThermX Microwave Ablation (MicroThermX) systems
and antennas from ADA. ADA is a leading medical specialty distributor in
Turkey with offices in the nation’s major metropolitan areas.

"Turkey is estimated to be the fifth fastest emerging economy in the world and
represents an exciting international market for our MicroThermX products,"
said Sam Maravich, Vice President of Sales and Marketing for BSD. "ADA
continues to purchase additional MicroThermX systems to meet the needs of the
expanding market in Turkey. Its prime location at the intersection of Europe
and Asia coupled with its booming industry is making Turkey an economic leader
in the Middle East. ADA represents several well-known medical device companies
and sells numerous products to the same physicians targeted for the
MicroThermX."

About the MicroThermX ^  Microwave Ablation System

The MicroThermX is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design of
the MicroThermX ^ is the first of its kind that allows delivery of higher
power levels using a single generator. The MicroThermX ^ utilizes innovative
synchronous phased array technology that was developed and patented by BSD to
provide larger and more uniform zones of ablation during a single procedure.
The MicroThermX ^ introduces into the Company’s product line innovative,
high-end disposables (SynchroWave antennas) that are used in each ablation
treatment and will provide a significant ongoing revenue stream. The soft
tissue ablation world market potential is estimated to exceed $2.3 billion.
The U.S. Food and Drug Administration (FDA) has granted the Company a 510(k)
clearance to market the MicroThermX for ablation of soft tissue. BSD has also
received CE Marking for the MicroThermX System, which allows BSD to market the
MicroThermX ^ in Europe. CE Marking is also recognized in many countries
outside of the EU, providing BSD the ability to market the MicroThermX ^ to a
number of international markets.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s MicroThermX
microwave ablation system has been developed as a stand-alone therapy to
employ precision-guided microwave energy to ablate (destroy) soft tissue. The
Company has developed extensive intellectual property, multiple products in
the market and established distribution in the United States, Europe and Asia.
Certain of the Company’s products have received regulatory approvals and
clearances in the United States, Europe and China. For further information
visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which
are subject to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Readers are cautioned that these forward-looking
statements are only predictions and may differ materially from actual future
events or results due to a variety of factors, including, among other things,
the demand for the Company’s products, the ability of the Company to produce
the products to meet the demand, global economic conditions and uncertainties
in the geopolitical environment and other risk factors set forth in the
Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking
statements in this release are based on limited information currently
available to the Company, which is subject to change, and the Company will not
necessarily update the information.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930